Astec LifeSciences Ltd.

Date: 31st July, 2026

To,
BSE Limited
P. J. Towers, Dalal Street, Fort
Mumbai – 400 001

Ref.: BSE Scrip Code No. "533138"

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra - Kurla Complex,
Bandra (East), Mumbai-400 051

Ref.: "ASTEC"

Debt Segment NSE:
NCD-ASTEC-ISIN: INE563J08023

<u>Sub.: Press Release</u>

The Board of Directors of Astec LifeSciences Limited ("the Company"), at its Meeting held on **Friday, 31st July, 2026**, has approved the Unaudited Financial Results (both Standalone and Consolidated) as per Indian Accounting Standards (IND AS) for the Quarter ended 30th June, 2026.

We enclose a copy of the Press Release and the same is being placed on the website of the Company.

Please take the above information on your records.

Thanking you,

Yours sincerely,

For Astec LifeSciences Limited

Tejashree Rohan Pradhan

Digitally signed by Tejashree Rohan Pradhan
DN: c=IN, o=Personal, title=1500, pseudonym=45ad7ca4dbc04d9e95b1cd79f249009d, 2.5.4.20=7e85e7813cc0727379015ad6d28a3b65295c6375608d78aea1ca152cafefaf7f, postalCode=400606, st=Maharashtra, serialNumber=cc444393f2150dc819f3d8164db345c555b40cb184b6ae8611cda7b9d64587a7, cn=Tejashree Rohan Pradhan
Date: 2026.07.31 17:26:24 +05'30'

Tejashree Pradhan
Company Secretary & Compliance Officer
(FCS 7167)

Encl.: As Above

ISO 9001 International Standards Certification ISO 9001:2015 | ISO 14001 International Standards Certification ISO 14001:2015 | OHSAS 45001 International Standards Certification OHSAS 45001/2018 | Responsible Care® Our commitment to sustainability

Regd. Office :
"Godrej One", 3rd Floor,
Pirojshanagar, Eastern Express Highway,
Vikhroli (East), Mumbai - 400079,
Maharashtra, India
Telephone No. : 022-25188010
Fax No. : 022-22618289
Email id : astecinfo@godrejastec.com
Website : www.godrejastec.com
CIN : L99999MH1994PLC076236

ASTEC LIFESCIENCES LIMITED

“Godrej One”, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (E), Mumbai-400079, India

CIN: L99999MH1994PLC076236

PRESS RELEASE

Mumbai, 31st July 2026: Astec LifeSciences Limited (“Astec”) has today announced its financial results for the first quarter.

FINANCIAL OVERVIEW

Q1 FY27 Financial Summary

- *The Company reported consolidated total income of ₹84.3 crore in Q1FY27 as compared to ₹91.6 crore in Q1FY26.*
- *The Company reported consolidated EBITDA of ₹0.1 crore in Q1FY27 as compared to EBITDA of ₹-10.5 crore in Q1FY26.*
- *The Company reported a Loss after tax of ₹-18.7 crore in Q1FY27 as compared to a loss of ₹-33.0 crore in Q1FY26.*

HIGHLIGHTS OF CONSOLIDATED FINANCIAL PERFORMANCE

(in ₹ crore)

Particulars	Q1FY27	Q1FY26	% Change
Total Income	84.3	91.6	-8.0%
Earnings before Depreciation, Interest and Tax (EBITDA)	0.1	-10.5	NM
Profit/(Loss) before Tax	(18.7)	(33.0)	NM
Profit/(Loss) after Tax	(18.7)	(33.0)	NM

NM: Not Measurable

CHAIRPERSON'S COMMENTS

Commenting on the performance, Mr. Vishal Sharma, Chairperson, Astec LifeSciences Limited, said:

The agrochemical sector is still dealing with the demand - supply imbalance since 2023 and this is expected to even out over the medium term which will structurally support the industry in a positive manner.

Astec reported consolidated income of ₹84.3 crore in Q1 FY27 versus ₹91.6 crore in Q1 FY26. The Company achieved EBITDA breakeven in the quarter compared to an EBITDA loss of ₹10.5 crore in the same period last year, despite lower revenues. The improvement is supported by favourable product mix, improved margins in both the Enterprise and Contract Manufacturing segments and enhanced capacity utilization at its plants.

Revenue from Enterprise Products grew 42% YoY to ₹51.8 crore in Q1 FY27, compared to ₹36.5 crore in Q1 FY26, primarily led by higher volumes and supported by improved realizations.

Revenue from CDMO Products stood at ₹31.8 crore in Q1 FY27 compared to ₹54.6 crore in Q1 FY26. The year-on-year decline was largely attributable to a high base in the corresponding quarter.

The company is taking steps to build its business development and growth capability along with new product introductions, while also exploring opportunities to drive efficiencies across its operations.

(in ₹ crore)

Revenue from Operations (₹ crore)	**Q1FY27**	**Q1FY26**	**% Change**
Category Breakdown			
Enterprise	51.8	36.5	41.6%
Contract Manufacturing & New Products	31.8	54.6	(41.8%)
Geography Breakdown			
Exports	33.3	45.9	(27.5 %)
Domestic	50.3	45.2	11.3%

- ENDS –

About Astec LifeSciences Limited

Astec LifeSciences Limited (Astec) was incorporated in 1994 and is engaged in the manufacturing of agrochemical active ingredients (technical), bulk, formulations and intermediate products. Astec has a healthy sales mix of both exports and domestic sales. Our exports are to over 18 countries including the United States and countries across Europe, West Asia, South-East Asia and Latin America and Africa.

For more information on the Company, please log on to www.godrejastec.com

For further information, please contact:

S. Varadaraj
Godrej Agrovet Limited
Email: s.varadaraj@godrejagrovet.com
Tel No.: +91 22 2519 4864

Deepak Ochani
Astec LifeSciences Limited
Email:deepak.ochani@godrejastec.com
Tel No.: +91 22 2519 5777

Amit Pendse
Godrej Agrovet Limited
Email: amit.pendse@godrejagrovet.com
Tel No.: +91 22 2519 4488